Partnerships, Licensing, Investments and M&A Deals and Trends for April 2017 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2017 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2017 11

2.2.1 Bain Capital Private Equity and Cinven Partners to Acquire Stada Arzneimittel for up to USD5.61 Billion 11

2.2.2 Fresenius to Acquire Akorn 12

2.2.3 Lonza Raise USD2.24 Billion in Rights Offering of Shares 12

2.2.4 PeptiDream Enters into Agreement with Janssen Pharma 13

2.2.5 Grifols Raises USD1.06 Billion in Public Offering of

3.2% Bonds Due 2025 13

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2017 14

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2017 14

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 16

3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2017 16

3.1.1 Top M&A Deals in April 2017 17

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2016– April 2017 18

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2017 19

3.2.1 Top Equity Offering Deals in April 2017 20

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2016– April 2017 21

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2017 22

3.3.1 Top PE/VC Deals in April 2017 23

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2017 24

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2017 25

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016–April 2017 26

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016–April 2017 27

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2017 28

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2016– April 2017 29

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 30

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2017 31

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 31

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2016– April 2017 32

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2016– April 2017 33

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2016– April 2017 34

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2017 36

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2017 36

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2017 37

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2016– April 2017 38

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2016– April 2017 39

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2016– April 2017 40

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2016– April 2017 42

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2017 43

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2017 43

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2017 44

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 45

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2017 45

5.1.1 Oncology – Deals of the Month 46

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2017 47

5.2.1 Central Nervous System – Deals of the Month 48

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2017 50

5.3.1 Infectious Diseases – Deals of the Month 51

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2017 52

5.4.1 Cardiovascular – Deal of the Month 53

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2017 54

5.5.1 Immunology – Deals of the Month 55

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, April 2017 56

5.6.1 Gastrointestinal – Deal of the Month 57

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2017 58

5.7.1 Metabolic Disorders – Deal of the Month 59

6 Deal Summary by Geography 60

6.1 Pharmaceuticals & Healthcare, North America Deals, April 2017 60

6.1.1 North America – Deals of the Month 61

6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2017 63

6.2.1 Europe – Deals of the Month 64

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2017 66

6.3.1 Asia-Pacific – Deals of the Month 67

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2017 68

6.4.1 Rest of the World – Deals of the Month 69

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 70

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2016– April 2017 70

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2016– April 2017 71

8 Further Information 72

8.1 Methodology 72

8.2 About GlobalData 73

8.3 Contact Us 73

8.4 Disclosure information 74

8.5 Disclaimer 74

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2017 11

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2017 15

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 17

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2017 17

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016– April 2017 18

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 20

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2017 20

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 21

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 23

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2017 23

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2016– April 2017 24

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2017 26

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2016– April 2017 27

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2016– April 2017 27

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2016– April 2017 28

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016– April 2017 29

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 30

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2017 31

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 32

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016– April 2017 33

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2016– April 2017 35

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 36

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 37

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016– April 2017 38

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2017 39

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016– April 2017 41

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 43

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2017 43

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2017 43

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2017 44

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 46

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 48

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 51

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 53

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 55

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 57

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 59

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 61

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 64

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 67

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 68

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2016– April 2017 70

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2016– April 2017 71

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2016– April 2017 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2017 14

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2017 14

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2016– April 2017 16

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016– April 2017 18

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2016– April 2017 19

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016– April 2017 21

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2016– April 2017 22

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016– April 2017 24

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2017 25

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2017 25

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2016– April 2017 26

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2016– April 2017 28

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016– April 2017 29

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 30

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 31

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016– April 2017 32

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016– April 2017 33

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2016– April 2017 34

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2016– April 2017 36

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 37

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016– April 2017 38

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016– April 2017 39

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2016– April 2017 40

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2016– April 2017 40

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 42

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2016– April 2017 45

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2016– April 2017 47

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2016– April 2017 50

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2016– April 2017 52

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2016– April 2017 54

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 56

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016– April 2017 58

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2016– April 2017 60

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2016– April 2017 63

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2016– April 2017 66

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2016– April 2017 68

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2016– April 2017 70

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2016– April 2017 71

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports